Author pages are created from data sourced from our academic publisher partnerships and public sources.
Focal gains of VEGFA and molecular classification of hepatocellular carcinoma.
Hepatocellular carcinomas represent the third leading cause of cancer-related deaths worldwide. The vast majority of cases arise in the context of chronic liver injury due to hepatitis B virus or… Expand
Pivotal role of mTOR signaling in hepatocellular carcinoma.
BACKGROUND & AIMS The advent of targeted therapies in hepatocellular carcinoma (HCC) has underscored the importance of pathway characterization to identify novel molecular targets for treatment. We… Expand
IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage.
BACKGROUND & AIMS IGF signaling has a relevant role in a variety of human malignancies. We analyzed the underlying molecular mechanisms of IGF signaling activation in early hepatocellular carcinoma… Expand
Unique genomic profile of fibrolamellar hepatocellular carcinoma.
BACKGROUND & AIMS Fibrolamellar hepatocellular carcinoma (FLC) is a rare primary hepatic cancer that develops in children and young adults without cirrhosis. Little is known about its pathogenesis,… Expand
MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a.
BACKGROUND & AIMS Hepatocellular carcinoma (HCC) is a heterogeneous tumor that develops via activation of multiple pathways and molecular alterations. It has been a challenge to identify molecular… Expand
Molecular classification and novel targets in hepatocellular carcinoma: recent advancements.
- Y. Hoshida, S. Toffanin, A. Lachenmayer, A. Villanueva, Beatriz Mínguez, J. Llovet
- Medicine, Biology
- Seminars in liver disease
- 30 January 2010
Hepatocellular carcinoma (HCC) is one of most lethal cancers worldwide. Strategic decisions for the advancement of molecular therapies in this neoplasm require a clear understanding of its molecular… Expand
Combination therapy for hepatocellular carcinoma: additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib.
BACKGROUND & AIMS Hepatocellular carcinoma (HCC) is a heterogeneous cancer in which sorafenib is the only approved systemic therapy. Histone deacetylases (HDAC) are commonly dysregulated in cancer… Expand
Gene-expression signature of vascular invasion in hepatocellular carcinoma.
BACKGROUND & AIMS Vascular invasion is a major predictor of tumor recurrence after surgical treatments for hepatocellular carcinoma (HCC). While macroscopic vascular invasion can be detected by… Expand
Hepatocellular carcinoma: novel molecular approaches for diagnosis, prognosis, and therapy.
- A. Villanueva, Beatriz Mínguez, A. Forner, M. Reig, J. Llovet
- Annual review of medicine
- 8 January 2010
The genomic era is changing the understanding of cancer, although translation of the vast amount of data available into decision-making algorithms is far from reality. Molecular profiling of… Expand
Pathogenesis of hepatocellular carcinoma and molecular therapies
- Beatriz Mínguez, V. Tovar, D. Chiang, A. Villanueva, J. Llovet
- Current opinion in gastroenterology
- 1 May 2009
Purpose of review Over the past decades, advances in the knowledge of the molecular pathogenesis of hepatocellular carcinoma (HCC) have allowed significant improvements in the therapeutic management… Expand